课题基金 / 基金详情

A master transcription factor driving cell lineage reprogramming in neuroendocrine prostate cancer development and progression

A master transcription factor driving cell lineage reprogramming in neuroendocrine prostate cancer development and progression
神经内分泌前列腺癌发生和进展中驱动细胞谱系重编程的主转录因子
批准号:
472404
负责人:
Wang Yuzhuo
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
已结题
起止时间:
2022-09-01 至 2023-09-01

项目摘要

项目成果

Wang Yuzhuo的其他基金

相似基金

相关文献

中文摘要
翻译
大多数前列腺癌依赖于雄激素受体(AR)信号传导来生长和存活。因此,靶向AR信号传导在前列腺癌的治疗中取得了成功。不幸的是,大约20%的患者的肿瘤最终会在更长的时间内复发。
英文摘要
Most prostate cancer relies on androgen receptor (AR) signaling for growth and survival. Therefore, targeting AR signaling had achieved success in the treatment of prostate cancer. Unfortunately, about 20% of patients' tumor eventually come back in a more
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization and Validation of MCT4-targeting Small Molecule Inhibitors for Treatment of Advanced Cancers
  • 批准号:
    451866
  • 项目类别:
    Operating Grants
  • 资助金额:
    $83.6万
  • 财政年份:
    2021
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
The role of PRDM16 in neuroendocrine prostate cancer development and aggressiveness
  • 批准号:
    420178
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2020
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Function and therapeutic potential of SUV420H2 in neuroendocrine prostate cancer
  • 批准号:
    390460
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.66万
  • 财政年份:
    2018
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Identification of HP1a as a key regulator and a novel therapeutic target for neuroendocrine prostate cancer
  • 批准号:
    357156
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2016
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
海外基金